文献速递白血病

卡非佐米联合诱导化疗治疗儿童复发或难治性急性淋巴细胞白血病

Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2026-01-01

这项2期研究在既往重度治疗的儿童复发/难治性急性淋巴细胞白血病(ALL)患者中评估卡非佐米(CFZ)联合VXLD方案诱导治疗,并与外部真实世界对照比较。诱导后完全缓解率在B-ALL为14.8%对7.8%,T-ALL为13.6%对9.1%,差异无统计学意义,研究未达到主要终点;B-ALL总缓解率42.6%对26.3%倾向CFZ-VXLD组。

要点

  • CFZ-VXLD诱导后完全缓解率未显著优于真实世界对照,研究未达主要终点。
  • B-ALL患者总缓解率42.6%对26.3%,倾向CFZ-VXLD组。
  • CFZ不良事件发生率与既往报道一致。

核心结论

  • CFZ-VXLD方案可能是一些经选择的儿童复发/难治性ALL患者的选择,但复发/难治性ALL仍存在未满足的医疗需求。

研究设计与样本

  • 2期研究,实验组为接受CFZ-VXLD诱导的复发/难治性ALL患者105例,年龄≥1月龄且<21岁。
  • 外部真实世界对照(EC)组为2000至2023年间在Therapeutic Advances in Childhood Leukemia sites接受治愈性方案的相似患者140例。
  • 比较分析采用逆概率治疗加权。

主要发现

  • B-ALL患者诱导后完全缓解率实验组14.8%对EC组7.8%(OR 2.04,95%CI 0.54-7.66)。
  • T-ALL患者诱导后完全缓解率实验组13.6%对EC组9.1%(OR 1.58,95%CI 0.47-5.31)。
  • B-ALL患者总缓解率实验组42.6%对EC组26.3%,倾向CFZ-VXLD组。
  • CFZ不良事件发生率与既往报道一致。

临床怎么用

  • CFZ-VXLD可作为部分经选择的儿童复发/难治性ALL患者的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report outcomes of the phase 2 study combining carfilzomib (CFZ) and VXLD (vincristine, dexamethasone, asparaginase, and daunorubicin; CFZ-VXLD) in heavily pretreated, pediatric patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). We investigated whether postinduction complete remission (CR) rates after CFZ-VXLD induction are superior to an external real-world control (EC). Patients aged ≥1 month to <21 years with R/R ALL received CFZ-VXLD induction, followed by optional consolidation (experimental arm). The EC arm included similar patients receiving real-world, curative-intent regimens at Therapeutic Advances in Childhood Leukemia sites between 2000 and 2023. The primary end point was CR after induction; overall response rate (ORR; CR/CR with partial/incomplete hematologic recovery/CR without platelet recovery) was a secondary end point. Comparative analyses used inverse probability of treatment weighting. Experimental and EC arms included 105 and 140 patients, respectively. CR rates after induction were 14.8% vs 7.8% (odds ratio [OR], 2.04; 95% confidence interval [CI], 0.54-7.66) in patients with B-cell ALL (B-ALL) and 13.6% vs 9.1% (OR, 1.58; 95% CI, 0.47-5.31) in patients with T-cell ALL. There was no statistically significant increase in postinduction CR for the CFZ-VXLD arm vs the EC arm and the study did not meet its primary end point. In patients with B-ALL, ORR was 42.6% vs 26.3%, favoring the CFZ-VXLD arm vs the EC arm. Adverse event rates with CFZ were consistent with previous reports. Overall, the CFZ-VXLD regimen may be an option for some selected pediatric patients with R/R ALL, and this study highlights that novel treatments for R/R ALL remain an area of unmet medical need. This trial was registered at www.clinicaltrials.gov as NCT02303821.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Locatelli F, Karakukcu M, Huynh V, et al. Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia. Blood Adv. 2026. PMID: 42234929. doi:10.1182/bloodadvances.2025019356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。